Data as of Sep 18, 2026 · Based on 3,315,446 AI responses across 10,525 prompts · See how Parse measures this
Transgene develops myvac, an individualized therapeutic vaccine platform that harnesses a patient’s immune system to fight cancer, built on viral vector engineering. Its pipeline includes TG4050 for head and neck cancer (adjuvant, Phase 2 ongoing) and TG4070 for non‑small cell lung cancer (adjuvant, Phase 1), with additional candidates TG6050 and BT-001 in development. The company aims to reshape early-stage cancer treatment with myvac and has published clinical data in Nature Communications showing Phase 1 findings for TG4050.
Parse Score